Chiusura precedente | 0,0100 |
Aperto | 0,0000 |
Denaro | 0,0100 x N/D |
Domanda | 0,0150 x N/D |
Min-Max giorno | 0,0100 - 0,0100 |
Intervallo di 52 settimane | 0,0100 - 0,1500 |
Volume | |
Media Volume | 92.931 |
Capitalizzazione | 1,374M |
Beta (mensile su 5 anni) | 0,39 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,0500 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
TORONTO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it has issued 1,056,441 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$126,773. In connection with this issuance, the Company also issued 17,691 common shares a price of CAD$0.12 per common share as payment of a finder's f
VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (“Newcourt”) (Nasdaq: NCAC), a special purpose acquisition company (“SPAC”) today announced the entry into an amended and restated business combination agreement (the “Amended and Restated Business Combination Agreement”),
Highlights: Drug development, Phase IIb clinical trial advanced planning underway in AustraliaPsyence granted worldwide licensing agreement to commercialize Filament’s PEX010 (25 mg) in palliative care with exclusivity in key marketsSuccessful completion of exports of medical grade psilocybin mushrooms to three key global marketsExtraction capabilities enhanced at Psyence’s production facilityChristopher Bull appointed to the board of directors to drive Psyence’s intellectual property strategy T